The role of ANGPTL3 in controlling lipoprotein metabolism by Tikka, Anna & Jauhiainen, Matti
REVIEW
The role of ANGPTL3 in controlling lipoprotein metabolism
Anna Tikka1 • Matti Jauhiainen1
Received: 30 October 2015 /Accepted: 16 December 2015 / Published online: 11 January 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Angiopoietin-like protein 3 (ANGPTL3) is a
secretory protein regulating plasma lipid levels via affect-
ing lipoprotein lipase- and endothelial lipase-mediated
hydrolysis of triglycerides and phospholipids. ANGPTL3-
deficiency due to loss-of-function mutations in the
ANGPTL3 gene causes familial combined hypobetal-
ipoproteinemia (FHBL2, OMIM # 605019), a phenotype
characterized by low concentration of all major lipoprotein
classes in circulation. ANGPTL3 is therefore a potential
therapeutic target to treat combined hyperlipidemia, a
major risk factor for atherosclerotic coronary heart disease.
This review focuses on the mechanisms behind ANGPTL3-
deficiency induced FHBL2.
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Introduction
Dietary fats are transported in the circulation in lipoprotein
particles, lipid-apolipoprotein complexes containing a
surface of phospholipid monolayer together with free
cholesterol and structural apolipoproteins (apo) and a
hydrophobic core including cholesterol esters and triglyc-
erides (TG) [1, 2]. In humans, TGs are packed and secreted
in the small intestine in apoB-48-containing chylomicrons
(CM) and in the liver in apoB-100 containing very low
density lipoproteins (VLDL) [1, 2]. TG in CM and VLDL
are hydrolyzed in circulation by lipoprotein lipase (LPL) [3].
The resulting free fatty acids are taken up by tissues pri-
marily via the function of CD36 transporter [4]. After
deprivation of TG, CM, and VLDL remnants are cleared via
specific liver receptors. SomeVLDL remnants are converted
in circulation, via hepatic lipase (HL) function, into
cholesterol-rich low density lipoproteins (LDL). LDL-re-
ceptors recognize LDL-bound apoB-100, resulting in the
uptake of the circulating LDL, mainly by the liver and by the
steroidogenic tissues [3]. Another class of lipoproteins, high
density lipoproteins (HDL), are functionally important in
reverse cholesterol transport, to clear excess accumulated
cholesterol from the periphery, and transport it back to the
liver for excretion [5]. Disturbances in lipoprotein metabo-
lism by genetic variants in genes affecting LPL activity
(ANGPTL3, APOC3, APOC2, APOA5), remnant clearance
(APOE, LIPC, LRP1), LDL receptor activity (PCSK9,
LDLR), lipoprotein secretion (APOB, MTP) and HDL
(APOA1, ABCA1) have been detected in humans [6, 7].
High blood levels of saturated fat and cholesterol are
major risk factors for coronary heart disease (CHD). Lipids
within apoB-containing lipoproteins can accumulate in
arterial intima and result in plaque formation and the
development of atherosclerosis [8]. LDL-Cholesterol is a
major cause for the generation of atherosclerotic plaques
[8], however, an independent predictive value for elevated
circulating TG in coronary heart disease (CHD) risk has
been demonstrated in prospective studies [9, 10]. Existing
pharmaceuticals, such as statins, fibrates, niacin, and fish
oil, which target LDL-cholesterol (LDL-C), TG, and HDL-
cholesterol (HDL-C) are prescribed alone or in various
combinations to target dyslipidemias [11]. ANGPTL3 is a
potential therapeutic target for alternative treatment of
combined hyperlipidemia.
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Characteristics of ANGPTL3
The angiopoietin-like proteins (ANGPTLs) form collec-
tively a specific family of secretory proteins sharing a
structural similarity to angiopoietins, the key factors that
regulate angiogenesis [12]. ANGPTL3 is a 460-amino-acid
(aa) polypeptide with a distinctive signal peptide sequence,
a N-terminal helical domain (predicted to form dimeric or
trimeric coiled-coil structures) and a C-terminal globular
fibrinogen homology domain [13]. The N-terminal
coiled—coil region (17–207 aa), specifically the amino—
acid domain 61–66, affects plasma triglyceride (TG) levels
via reversibly inhibiting catalytic activity of LPL [14, 15].
The fibrinogen-like domain (207–460 aa) binds to integrin
avb3 receptor and affects angiogenesis [16]. A short linker
region (at 221–222 and 224–225) between N- and C-ter-
minal domains functions as a furin cleavage site. The
truncated form of cleaved ANGPTL3 displays enhanced
inhibitory activity for LPL and endothelial lipase (EL)
suggesting that furin-facilitated cleavage of ANGPTL3 is
physiologically important [14, 17]. Angiopoietin-like pro-
tein 8 (ANGPTL8), an insulin-induced protein sharing
sequence homology with ANGPTL3, may also regulate
ANGPTL3 proteolytic activation in vivo [18–20].
The association of ANGPTL3 with lipoprotein meta-
bolism was discovered in hypertriglyceridemic and
hyperglycemic obese KK mice, which spontaneously
inherited a recessive trait causing low levels of triglyceride
in plasma [21] and elevated post-heparin LPL activity [22].
The hypolipidemic mice carried a 4-base pair insertion in
exon 6 introducing a stop codon in the Angptl3 gene. Low
lipid levels in the mutant mice were normalized by an
intravenous injection of ANGPTL3 [21]. When the region
including Angptl3 LOF was introduced to atherogenic
apoE-knock out mice, the prevalence of atherosclerotic
lesions significantly declined [23] indicating that
ANGPTL3-deficiency and the resulting hypolipidemia in
these mice, was protective against the development of
atherosclerosis.
Population studies and clinical characterization
of ANGPTL3 sequence variants in humans
In humans, both common and rare genetic variants in
ANGPTL3 gene have been reported to associate with
plasma lipids. Three genome-wide scans (n = 8800) from
Finnish and Italian subjects showed a strong association
between ANGPTL3 and plasma TG levels [6]. Since then,
more data have been published on the association between
ANGPTL3 variants and plasma TG, LDL, HDL, and total
cholesterol levels [24]. As much as 4 % of the Dallas Heart
Study population (n = 3,551) with plasma TG in the
lowest quartile carried rare LOF mutations in ANGPTL3,
ANGPTL4, or ANGPTL5 [25].
Genetic LOF variants in ANGPTL3 cause a rare reces-
sive disorder known as familial combined hypobetal-
ipoproteinemia (FHBL2, OMIM # 605019). FHBL2
subjects display a distinct plasma lipid phenotype including
very low VLDL, LDL, and HDL levels, and consequently
low total TG and cholesterol levels ([26], see Table 1).
Involvement of ANGPTL3 LOF mutation in FHBL2 was
discovered by genome sequencing of two siblings of
European descent who were compound heterozygotes for
two distinct nonsense mutations in ANGPTL3 (p.E129*
and p.S17*) [27]. p.S17* LOF mutation is common among
the residents of a town Campodimele (Latina, Italy), of
which 9.4 % carry the mutant variant [26]. Only the
homozygous carriers of p.S17*, who have unde-
tectable levels of ANGPTL3 in circulation, manifest low
lipid and lipoprotein levels whereas heterozygote carriers,
with a 50 % reduction in circulatory ANGPTL3, are not
affected by FHBL2 (26, 34, see Table 1). In addition to
p.S17* and p.E129* LOF mutations, more subjects with
rare LOF variants in ANGPTL3 are detected in Spanish and
Italian FHBL2 families [28–30]. Among 78 sequenced
American and Italian FHBL2 subjects, 8 subjects carried 9
different nonsense mutations in ANGPTL3, with no muta-
tions in APOB, PCSK9, or MTP. The prevalence for
ANGPTL3 LOF mutations in all of the FHBL2 cases was
therefore 10 % [31].
ANGPTL3 function
An increasing number of evidence indicates that the
hypolipidemic phenotype in ANGPTL3-deficiency is dri-
ven by accelerated turnover of lipoproteins and the
resulting altered energy substrate distribution among tis-
sues (see Fig. 1).
ANGPTL3 and lipoprotein clearance
Lipoprotein lipase (LPL) is located on the luminal side of
the vascular endothelium of the capillaries in extra hepatic
tissues [3]. LPL plays a critical role in hydrolyzing TG
carried by VLDL and chylomicron (CM) particles in the
circulation. Activity of LPL in white adipose tissue (WAT)
is elevated in fed state and reduced in fasted state [3].
Therefore, in the fed state, the flow of dietary fat is pri-
marily targeted into WAT, not into skeletal muscle, which
would rely on glucose in energy production [3]. During
fasting, skeletal muscle is believed to be the main site for
LPL activity [3]. Endothelial lipase (EL) is located on the
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luminal side of the vascular endothelial cells (like LPL)
and shares 44 % homology with LPL and 41 % with
hepatic lipase (HL) [32]. Unlike LPL, EL is more specific
in hydrolyzing lipoprotein phospholipids, especially in
HDL-particles, rather than TG [33].
Both LPL and EL activities are increased in humans and
mice with Angptl3 deficiency [34–36]. There are no reports
on enhanced HL activity in ANGPTL3-deficiency. In
Angptl3-knockout mice, TGs in postprandial lipoproteins
were directed in brown adipose tissue (BAT) and muscle
Table 1 Characteristic lipid, apolipoprotein, and Angptl3 levels of FHBL2 subjects with p.S17* mutation in the ANGPTL3 gene
Parameter Homozygote p.S17*-carriers (n = 5) Heterozygote p.S17*-carriers (n = 17) Non-carriers (n = 22)
Sex (W/M) 2/3 8/9 11/11
Age 63.6 ± 10 50.1 ± 20 51.8 ± 19
BMI 31.5 ± 7 28.3 ± 4 28.3 ± 5
Angptl3 (ng/mL) 0* 97 ± 96* 233 ± 145
FFA (lmol/L) 344.5 ± 292.2 486.2 ± 239.9 563 ± 249.9
ApoB (g/l) 1.0 ± 0.08* 1.5 ± 0.3 1.5 ± 0.4
ApoA-I (g/l) 0.5 ± 0.2* 1.3 ± 0.3 1.3 ± 0.2
TG (mmol/l) 0.5 ± 0.10* 1.1 ± 0.6 1.5 ± 0.7
CHOL (mmol/l) 2.3 ± 0.4* 4.6 ± 0.8 5.2 ± 1.1
LDL-CHOL (mmol/l) 1.4 ± 0.2* 2.6 ± 0.6 3.1 ± 0.8
HDL-CHOL (mmol/l) 0.7 ± 0.21* 1.5 ± 0.3 1.5 ± 0.4
Values in Table are modified from Robciuc et al. [34]. Values are reported as mean ± SD * p\ 0.05. FFA values N = 7 for homozygotes,
N = 47 for heterozygotes and N = 58 for non-carriers
ANGPTL3
CM 
secreon ?
VLDL 
secreon
LPL 
acvity
Lipolysis
LPL 
acvity
Fig. 1 Function of ANGPTL3
in lipoprotein metabolism.
ANGPTL3-deficiency causes
enhanced activity of lipoprotein
lipase (LPL) in the muscle and
adipose tissue and accelerated
clearance of TG-rich
lipoproteins. Decreased release
of FFA, from adipose tissue
(lipolysis), hypothetically
results in scarcity of FFA
substrates for hepatic de novo
synthesis of TG and cholesterol,
and consequently decreased
lipidation of VLDL. There are
no reports on whether
ANGPTL3-deficiency would
affect the lipidation and
secretion of intestinal TG-
enriched chylomicron (CM)-
particles
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instead of WAT [37]. The study indicates that ANGPTL3-
deficiency might induce LPL activity in the oxidative tis-
sues during feeding and accelerate the clearance of TG-rich
particles. Since LPL or EL do not hydrolyze cholesterol
esters, the mechanism for low LDL-C levels in ANGPTL3-
deficiency, has remained elusive. Wang et al. reported that
LDL-cholesterol levels were equally reduced in wildtype
mice and LDLR, LRP1, or APOE knockout mice treated
with ANGPTL3 inactivating antibody [38]. These results
suggest that reduced LDL-cholesterol in ANGPTL3-defi-
ciency is not caused by enhanced clearance of cholesterol
via LDL-receptors. Alternatively, reduced LDL-C levels
may be a result of lower secretion rates of LDL precursors,
hepatic VLDL particles.
ANGPTL3-deficiency in FHBL2 causes a reduction in
HDL-particles, the facilitators of reverse cholesterol
transport. As increased activity of EL is associated with
reduced plasma HDL-cholesterol (HDL-C) levels [39],
higher activity of EL might contribute to low HDL levels
demonstrated in ANGPTL3-deficiency. Even though low
HDL is an established risk factor for atherosclerosis [40],
decreased HDL levels did not result in accelerated
atherosclerosis in ANGPTL3-deficient subjects, probably
because of the lifelong exposure to low levels of VLDL
and LDL [30]. The lipolysis of TG-rich lipoproteins and
HDL, via LPL and EL, respectively, may result in
increased turnover of lipoprotein remnants and therefore
low plasma apoB and apoA-I levels.
The role of ANGPTL3 in lipoprotein production
Hepatic VLDL synthesis relies on the availability of
triglycerides which are synthesized from substrates derived
from the supply of free fatty acids from adipocytes [41],
from VLDL and chylomicron remnants [1, 2] and from
simple sugars [42] via the portal vein. Insulin signaling
reduces hepatic VLDL synthesis and secretion which is
manifested by reduced lipidation of TG-rich VLDL parti-
cles [43]. Mice treated with monoclonal ANGPTL3 inac-
tivating antibody did not show lower production rates for
apoB-100 [38], the major structural protein of VLDL,
indicating that there are no changes within the amount of
secreted VLDL particles. However, the amount of TG in
each VLDL particle might be declined [44]. Reduced lip-
idation of VLDL in ANGPTL3-deficiency may be caused
by decreased supply of free fatty acids from the circulation
into the liver. These observations are in agreement with the
reported low FFA levels in ANGPTL3-deficient subjects
[34]. A metabolic study with ANGPTL3-silenced hepato-
cytes suggests that silencing of ANGPTL3 causes a shift in
substrate utilization to favor glucose, instead of FFA [44],
which supports the theory of attenuated FFA supply into
the liver.
Cholesterol is either ingested from nutrition or synthe-
sized de novo by the liver. Reduced availability of sub-
strates may decrease hepatic de novo synthesis of
cholesterol resulting in the secretion of cholesterol-poor
VLDL in ANGPTL3-deficiency. Interestingly, ANGPTL3
is a downstream target for liver X receptors (LXR’s),
transcription factors with sterol binding ability [45].
Oxysterols, cholesterol, and other cholesterol metabolites
are natural ligands for LXRs, and LXR activation protects
the liver from cholesterol overload by stimulating bile acid
formation and excretion, lipogenesis, HDL-mediated
reverse cholesterol transport, and glucose metabolism [46,
47]. Synthetic LXR ligands and a high cholesterol diet
induce Angptl3 expression in the liver [48, 49]. On the
contrary, low LXR, and low Angptl3 expression (in
ANGPTL3-deficiency) may therefore be linked to hypoc-
holesterolemic and antilipogenic status in the liver.
Adipose tissue
White adipose tissue (WAT) serves as the primary tissue
for storage of triglycerides. Postprandial TGs are primarily
directed to WAT via LPL-mediated hydrolysis [3]. In
Angptl3-knockout mice, TG-derived FFA uptake was
decreased in WAT while elevated in BAT and muscle.
Such a shift in substrate distribution between tissues,
however, did not result in differences in TG-content of the
liver, adipose tissue, and heart, possibly because reduced
lipid uptake in WAT was balanced by elevated glucose
uptake [37].
TG-deposits in adipose tissue are dismantled by lipoly-
sis, a catabolic breakdown of TG mediated by concerted
action of adipose TG lipase (ATGL), and hormone sensi-
tive lipase (HSL) [41]. Lipolysis is inhibited in the post-
prandial state by elevated insulin concentrations [50].
During fasting, lipolytic activity increases the release of
FFA and free glycerol into circulation, to provide sub-
strates for energy production in the oxidative tissues [41].
In Angptl3-knockout mice, both FFA and glycerol were
reduced in plasma and were preserved by administration of
ANGPTL3 [51]. Therefore, absence of circulatory
ANGPTL3 (in ANGPTL3-deficiency) may decrease FFA
lipolysis in the adipose tissue and consequently reduce
plasma FFA and glycerol levels.
Conclusions
Several mutations in the APOB, PCSK9, and MTP genes
result in familial hypobetalipoproteinemia (FHBL) and
abetalipoproteinemia (ABL) defined as low, or absent
levels of apoB-100, and LDL-C in plasma [52, 53]. LOF
mutations in the ANGPTL3 results in familial combined
190 Endocrine (2016) 52:187–193
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hypobetalipoproteinemia (FHBL2) with reduced levels of
all major lipoprotein classes (VLDL, LDL, HDL) in
plasma. The hypolipidemic phenotype caused by
ANGPTL3 inactivation is likely an outcome of increased
activity of two lipolytic enzymes, LPL, and EL, which
account for increased turnover of lipoproteins, and reduced
TG and HDL levels in the plasma. Low plasma FFA levels
in ANGPTL3-deficiency may be due to decreased lipolysis
in the adipose tissue which may also contribute to reduced
lipidation of hepatic VLDL, and LDL, and consequently
low TG and LDL-C. The impact of ANGPTL3-deficiency
on intestinal chylomicron production remains unknown.
However, there are no reports on steatorrhea among
ANGPTL3-deficient subjects.
No adverse health effects or developmental alterations
during early or later life-time are reported in ANGPTL3-
deficient p.s17* LOF mutation carriers [26, 34]. Perhaps
ANGPTL3 may have been functionally important during
long periods of fasting to primarily ensure FFA release from
TG-deposits, via controlling lipolytic activity, and by guid-
ing energy substrates into either oxidative tissues orWAT by
selective LPL inhibition. Such tight regulation between
energy storage and substrate release might be important
during times with less frequent access to energy rich diet.
The striking hypolipidemic phenotype in ANGPTL3
deficiency shows the potential of ANGPTL3 inactivation as
a treatment for correcting hyperlipidemia. Therefore,
ANGPTL3 inactivation may have important therapeutic
implications for treatment of metabolic syndrome, type 2
diabetes, and patients in high risk of heart disease. The first
reports on ANGPTL3 inhibitors have shown promising
results. Administration of ANGPTL3 inactivating antibody
to monkeys and dyslipidemic mice reduced circulating
plasma levels of TG, LDL-cholesterol, and HDL-choles-
terol significantly [54]. Another strategy for ANGPTL3
inactivation, and perhaps a better one to avoid immune
response associated with administration of antibodies,
could be selective antisense inhibition of ANGPTL3
expression in the liver. Despite favorable reduction in
LDL-C and TG, it is still uncertain whether decreased
HDL-C would have an influence on overall CVD risk in
ANGPTL3-inhibitor treated patients.
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